Stay updated with breaking news from Drug Discovery Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company's Lead Joint Researcher Professor Perán to Present Latest PRP Research Propanc Biopharma, Inc. (OTC Pink: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel
Wednesday morning saw healthcare stock Race Oncology , developer of cancer drug treatments and melanoma therapies, provide an update on an improved formulation of its Zantrene (RC220) product.
OICR’s Drug Discovery Team is made up of 26 drug discovery scientists housed in state-of-art facilities with a mission to help Ontario’s researchers efficiently translate cancer related discoveries into novel oncology therapies. This team has “identified five of the most promising early stage oncology drug development projects in the province,” said Dr. Tom Hudson, the OICR’s president and scientific director. “OICR is pleased to support these Ontario-based research projects and we look forward to collaborating with our partners to help move them to the next stage of developmen...
MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company appointed Ms. Belen Toledo MSc., a biotechnologist specializing in cell regenerative medicine, to evaluate the
Propanc Biopharma Provides Shareholder Update MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today on the progress of the Company, recent developments and forecast for 2021, as the Company prepares for entering clinical development for its lead product candidate, PRP, for the treatment and prevention of metastatic cancer. PRP represents a novel therapeutic approach, targeting and eradicating can...